PDE4B and colorectal carcinoma: This reorganization is characterized by the apical assembly of tight junction markers such as ZO-1 and E-cadherin, alongside an increase in apoptosis markers like caspase-3, suggesting that targeting PDE4B could be a viable therapeutic strategy in KRAS-driven CRC [93].